Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs |
|
Farzamfar B,
Abdollahi M,
Ka'abinejadian S,
Heshmat R,
Shahhosseiny MH,
Novitsky Y.A,
Farhadi M |
Pages: 15-19 |
In vivo and in vitro genotoxicity studies of Semelil (ANGIPARSTM) |
|
Khorram Khorshid HR,
Sadeghi B,
Heshmat R,
Abdollahi M,
Salari P,
Farzamfar B,
Madani SH |
Pages: 20-24 |
Effect of ANGIPARSTM, a new herbal drug on diabetic foot ulcer: A phase 2 clinical study |
|
Masoompour SM,
Bagheri MH,
Borhani Haghighi A,
Novitsky YA,
Sadeghi B,
Gharibdoust F,
Larijani B,
Ranjbar Omrani G |
Pages: 31-34 |
Effects of intravenous Semelil (ANGIPARSTM) on diabetic foot ulcers healing: A multicenter clinical trial |
|
Larijani B,
Heshmat R,
Bahrami A,
Delshad H,
Ranjbar Omrani G,
Mohammad K,
Heidarpour R,
Mohajeri Tehrani MR,
Kamali K,
Farhadi M,
Gharibdoust F,
Madani SH |
Pages: 35-40 |
Intravenous Semelil (ANGIPARSTM) as a novel therapy for pressure Ulcers: A randomized clinical trial |
|
Shamimi Nouri K,
Heshmat R,
Karimian R,
Nasli E,
Larijani B,
Novitsky YA,
Farhadi M,
Gharibdoust F |
Pages: 49-53 |
Topical application of Semelil (ANGIPARSTM) in treatment of pressure ulcers: A randomized clinical trial |
|
Shamimi Nouri K,
Karimian R,
Nasli E,
Kamali K,
Chaman R,
Farhadi M,
Madani SH,
Larijani B,
Khorram Khorshid HR |
Pages: 54-57 |